Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Deferasirox: Oral Iron Chelator Mechanisms & Clinical Benchm

    2026-05-06

    Deferasirox: Oral Iron Chelator Mechanisms & Clinical Benchmarks

    Executive Summary: Deferasirox is an orally administered trivalent iron chelator that binds Fe³⁺ at a 2:1 molar ratio, forming soluble complexes for efficient iron removal in transfusion-related overload conditions (product_spec). It modulates mitochondrial reactive oxygen species (ROS) and the NF-κB pathway, influencing gene expression related to hematopoietic differentiation (internal). The drug demonstrates low affinity for zinc and copper, reducing off-target toxicity (product_spec). Clinical administration ranges from 20–40 mg/kg orally once daily, with fecal excretion accounting for ~84% (product_spec). Deferasirox is provided by APExBIO as SKU A8639 for research and clinical workflows.

    Biological Rationale

    Iron is essential for cellular metabolism, DNA synthesis, and oxygen transport, but excess iron catalyzes production of harmful ROS, contributing to tissue injury and carcinogenesis (Ren et al., 2025). Chronic transfusions in disorders like thalassemia, sickle cell disease, and myelodysplastic syndromes (MDS) cause pathological iron accumulation (product_spec). Iron chelation therapy mitigates these risks by sequestering labile iron, preventing ROS-mediated damage (internal). Recent research links iron metabolism to cancer cell survival, emphasizing the translational impact of Deferasirox beyond traditional iron overload settings (internal).

    Mechanism of Action of Deferasirox

    Deferasirox (4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid, MW 373.37) chelates Fe³⁺ with high specificity, forming a 2:1 complex (product_spec). This process enhances iron excretion predominantly via feces (84%) and minimally through renal elimination (8%) (product_spec). The compound interferes with mitochondrial respiratory chain function, elevating ROS levels and modulating the NF-κB pathway (internal). Deferasirox downregulates MYC target genes in hematopoietic progenitors and SPI1 (PU.1) targets in neutrophils, inhibiting terminal myeloid differentiation (product_spec). Its IC₅₀ for murine ER::HOXB8 cells ranges from 2.1–3.0 μM under normoxia and 14.8–21.7 μM under hypoxia, illustrating oxygen-dependent efficacy (product_spec). It exhibits low affinity for zinc/copper, reducing the risk of micronutrient depletion (product_spec).

    Evidence & Benchmarks

    • Deferasirox binds Fe³⁺ at a 2:1 molar ratio to form excretable complexes (source: product_spec).
    • Oral dosing of 20–40 mg/kg/day is clinically established for iron overload disorders (source: product_spec).
    • Fecal excretion is the primary elimination route (84%), with minor renal clearance (8%) (source: product_spec).
    • IC₅₀ in murine ER::HOXB8 cells: 2.1–3.0 μM (normoxia), 14.8–21.7 μM (hypoxia) (source: product_spec).
    • Modulation of NF-κB signaling and mitochondrial ROS generation demonstrated in preclinical assays (source: internal).
    • Gene expression of MYC (hematopoietic progenitors) and PU.1 targets (neutrophils) is downregulated by Deferasirox (source: product_spec).
    • Gastrointestinal discomfort, skin rash, and mild creatinine elevation are the most common adverse effects (source: product_spec).
    • Deferasirox is insoluble in water; DMSO solubility ≥37.28 mg/mL, ethanol solubility ≥2.94 mg/mL with ultrasound (source: product_spec).
    • Should not be co-administered with aluminum-containing compounds (source: product_spec).

    Compared to this workflow guide (which focuses on troubleshooting and workflow optimization), the present article expands on molecular mechanisms and clinical benchmarks for Deferasirox. For a deeper dive into ferroptosis and iron metabolism modulation, see this mechanistic review, which is complemented here by protocol and safety details. Additionally, this summary outlines preclinical tumor growth inhibition, while the current dossier provides a broader clinical and biochemical perspective.

    Applications, Limits & Misconceptions

    Deferasirox is indicated for iron overload in thalassemia, sickle cell disease, and MDS, where it reduces transfusion requirements and improves erythropoiesis (source: product_spec). Emerging research supports its use as an antitumor agent targeting iron metabolism and ferroptosis, with demonstrated efficacy in preclinical models (internal). Deferasirox does not chelate iron from transferrin-bound pools at physiological pH, limiting its effect to labile iron (product_spec). Its low affinity for zinc and copper supports a favorable safety profile, though renal monitoring is mandatory during therapy (product_spec).

    Common Pitfalls or Misconceptions

    • Deferasirox is not effective for acute iron poisoning or non-transfusional iron overload (source: product_spec).
    • It cannot reverse established organ damage from long-standing iron overload—early intervention is required (source: workflow_recommendation).
    • Co-administration with aluminum-containing compounds is contraindicated due to potential toxicity (source: product_spec).
    • Not recommended in patients with severe renal impairment (source: product_spec).
    • Water insolubility necessitates use of DMSO or ethanol for in vitro work (source: product_spec).

    Workflow Integration & Parameters

    Protocol Parameters

    • in vivo dosing | 20–40 mg/kg/day orally | iron overload (clinical) | Standard protocol for transfusional iron overload | product_spec
    • in vitro concentration | 3–20 μM | cell-based iron chelation/apoptosis | Reflects IC₅₀ and mechanistic studies | product_spec
    • solubility in DMSO | ≥37.28 mg/mL | stock preparation | Required due to poor water solubility | product_spec
    • solubility in ethanol (ultrasonic) | ≥2.94 mg/mL | alternative solvent | For ethanol-compatible workflows | product_spec
    • storage | solid at -20°C | long-term storage | To preserve stability; solutions not for long-term storage | product_spec

    Deferasirox by APExBIO (SKU A8639) is supplied as a solid for research and clinical use. When integrating into workflows, avoid aluminum-containing co-medications and monitor renal function periodically. For detailed troubleshooting and comparative advantages, refer to internal workflow recommendations.

    Conclusion & Outlook

    Deferasirox is a validated oral iron chelator with robust clinical utility in iron overload syndromes and expanding roles in cancer research targeting iron metabolism (internal). Its selective Fe³⁺ binding, low off-target metal affinity, and mitochondrial/ROS modulation underpin both safety and efficacy. Current evidence supports ongoing investigation in ferroptosis-driven tumor models and metabolic adaptation mechanisms (Ren et al., 2025). Further work may clarify optimal combinatorial regimens and long-term outcomes, but present data justify its incorporation in both clinical and translational protocols.